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A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2
overexpressing breast cancer cells via cytochrome c dependent mechanisms
Bin Chen , Bin Su , Shiuan Chen
Introduction
Adenocarcinoma of the breast is the most common cancer in
women in the United States and ranks second only to lung cancer
as a cause of cancer related mortality. About 182,460 women in
the nation were found to have invasive breast cancer in 2008.
About 40,480 women will die from the disease this year [1].
Currently over 2 million women living in the United States have
been treated for breast cancer. About 25 30% of breast cancer
patients have human epidermal growth factor 2 (Her2) over
expressed tumors, which means that their cancer cells depend on
the Her2 pathway to proliferate [2]. Her2, also referred as ErbB2, is
a member of the ErbB receptor tyrosine kinases family. The ErbB
family consists of four members: epidermal growth factor (EGF)
receptor/ErbB1, ErbB2 (Her2), ErbB3, and ErbB4. They can form
both homo or heterodimers, which then stimulates the intrinsic
tyrosine kinase activity of the receptors and triggers autopho
sphorylation of specific tyrosine residues within cytoplasmic
domain and drives cancer cell proliferation, invasion and
differentiation [3 7]. Her2 appears to be the preferred partner
of the other ligand bound ErbBs [8]. The high level of Her2 protein
is generally due to amplification of the Her2 gene in tumors and
results in constitutive activation of the receptor. Several studies
have shown that patients with breast cancer that overexpressed
Her2 are associated with increased disease recurrence, worse
prognosis and lower survival [2,9]. It has been observed that
targeting Her2 results in efficient inhibition of breast cancer cell
proliferation, which proceeds via inhibition of intracellular
signaling pathways and directly targets various members of the
cell growthmachinery [10]. Currently, there are two types of drugs
that target Her2. The first one is Her2monoclonal antibody such as
trastuzumab approved by FDA in 1998; the second type is
intracellular tyrosine kinase inhibitors such as lapatinib approved
by FDA in 2007. In addition, other approaches are also being
investigated to develop agents that are able to selectively inhibit
Her2 breast cancer cell growth [11].
A growing body of experimental and epidemiological evidence
suggests that the use of NSAIDs (non steroidal anti inflammatory
drugs) may decrease the incidence of mammary cancer, tumor
burden, and tumor volume [12 15]. Celecoxib, a COX 2 (cycloox
ygenase 2) selective inhibitor, has strong chemopreventive activity
against mammary carcinoma in rats in some studies [16]. In
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addition to COX inhibition, these small molecules also target other
molecular pathways. For example, celecoxib is able to block
phosphoinositide 3 kinase (PI3K)/phosphoinositide dependent
kinase (PDK)/Akt pathway to induce apoptosis in prostate cancer
cells [17,18]. Nimesulide (4 nitro 2 phenoxymethane sulfoani
lide) is a non steroidal anti inflammatory drug with a preferential
cyclooxygenase 2 inhibitory activity and is available in some Asian
and European countries since 1985. In fact, the anti inflammatory
activity of nimesulide is almost the same as that of indomethacin,
but its alcerogenic potential is much weaker. Studies suggest that
nimesulide can induce apoptosis in liver and lung cancer cells; it
also suppressed the development of 2 amino 1 methyl 6 pheny
limidazo [4,5 b] pyridine (PhIP) induced mammary gland carci
nogenesis in rats [19 23]. Furthermore, derivatives of nimesulide
have been found to be much more active in suppressing SKBR 3
breast cancer cell growth than nimesulide [24].
Our goal is to identify new agents that would selectively inhibit
the growth of Her2 overexpressing breast cancer cells, and then
investigate the mechanism of the pharmacological activity. In this
paper, one lead compound (compound 76) from the nimesulide
derivative pool was synthesized (Fig. 1) according to previous
procedure [24], and their biological effect on breast cancer cell
growthwas investigated in a panel of breast cancer cell lineswhich
include SKBR 3, BT474, MDA MB 453, MCF 7 and MDA MB 231.
Compound 76 selectively inhibited SKBR 3, BT474 and MDA MB
453Her2 overexpressing breast cancer cell proliferation, but it was
not effective on the proliferation of MCF 7 andMDA MB 231 Her2
negative cells. Because of the typical apoptotic morphological
changes which includes cell shrinkage and condensation of the
nucleus after the treatment of compound 76, several assays were
performed to determine the possibility of potential apoptosis
inducing effects of compound 76 in SKBR 3 and BT474 cancer cells.
The results indicate that compound 76 significantly induced
apoptosis mediated by the mitochondria in the cells. Since
synthesis of compound 76 derivatives has been well established,
new analogs could be generated to further optimize the structure
and achieve more active agents.
Materials and methods
Reagents
Trypsin and all enzymes were obtained from Invitrogen
(Carlsbad, CA). All the chemical reagents and solvent were from
Sigma Aldrich (St. Louis, MO). For in vitro experiments, compound
76 at various concentrations were dissolved in DMSO. All
antibodies were from Cell Signaling (Danvers, MA) or Santa Cruz
Biotechnology (Santa Cruz, CA). All the synthesis reagents were
from Aldrich (Aldrich, Milwaukee, WI).
Synthesis of compound 76
Compound 76 was synthesized according to the published
procedure [24], and the structure and purity were confirmed by
NMR. Cyclohexanecarboxylic acid [3 (2,5 dimethyl benzyloxy)
4 (methanesulfonyl methyl amino) phenyl] amide: 1H NMR
(500 MHz, CDCl3) d 8.07 (1H, s), 7.29 (2H, m), 7.10 (3H, m),
6.66 (1H, d, J = 8.5 Hz), 5.07 (2H, s), 3.19 (3H, s), 2.71 (3H, s), 2.35
(3H, s), 2.34 (3H, s), 2.24 (1H, m), 1.96 (2H, m), 1.86 (2H, m), 1.73
(1H, m), 1.54 (3H, m), 1.27 (2H, m). Purity (97%) is measured by
HPLC analysis. A 1.00 mg/mL stock solution of compound 76 was
prepared in acetonitrile. HPLC analysis was performed on a
HP1100 system (Hewlett Packard, Palo Alto, CA), which consists
of a vacuum degasser, binary pumps, column compartment, and a
UV detector. Reversed phase HPLC was carried out on a C18
column (3.0 mm  150 mm, 5 mm) from Beckman (Beckman
Instruments, Fullenton, CA) at room temperature with a flow
rate of 0.5 mL/min. Gradient mobile phase (mobile phase A:
water; mobile phase B: acetonitrile) was employed to run 20 min.
An injection volumeof 25 mLwasused. TheUVdetectorwas set up
at 254 nm and 330 nm.
Cell culture
SKBR 3, MDA MB 231, MCF 7, BT474 and MDA MD 453 cells
were obtained from ATCC (Rockville, MD). MDA MD 453 cells
were maintained in DMEM/F12 medium supplemented with 10%
fetal bovine serum (FBS) and 100 U/mL penicillin streptomycin.
All the other cell lines were cultured in MEM, supplemented with
10% fetal bovine serum (FBS), 2 mmol/L L glutamine, 1 mmol/L
sodium pyruvate, and 100 U/mL penicillin streptomycin. Cell
cultures were grown at 37 8C, in a humidified atmosphere of 5%
CO2 in a Hereaus CO2 incubator.
Cell proliferation
The effect of compound 76 on breast cancer cell proliferation
was assessed by using the 3 (4,5 dimethylthiazol 2 yl) 2,5
diphenyl 2H tetrazolium bromide assay (MTT) in six replicates.
Cells were grown in culture medium in 96 well, flat bottomed
plates for 24 h, and were exposed to various concentrations
of compound 76 dissolved in DMSO (final concentration
0.1%) in media at different time intervals. Controls received
DMSO vehicle at a concentration equal to that in drug treated
cells. The medium was removed, replaced by 200 mL of 0.5 mg/
mL of 3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyl 2H tetrazo
lium bromide in fresh medium, and cells were incubated in
the CO2 incubator at 37 8C for 2 h. Supernatants were removed
from the wells, and the reduced 3 (4,5 dimethylthiazol 2 yl)
2,5 diphenyl 2H tetrazolium bromide dye was solubilized in
200 mL/well DMSO. Absorbance at 570 nm was determined on a
plate reader.
Morphological examination of apoptotic changes
Cells were treated with compound 76 at various concentration
for 48 h, and then stained with Hoechst 33342 (5 mg/mL) at 37 8C
for 30 min. The stained cells were examined by fluorescence
microscopy using a microscope (Nikon, Tokyo) equipped with an
epi illuminator and appropriate filters.
Fig. 1. Structures of nimesulide, compound 76 (top panel); Her2 and ER status in five
breast cancer cell lines (bottom panel). Cells were harvested and Her2 and ER
proteins were analyzed byWestern blotting of cell extracts with specific antibodies
as described in Section 2.
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Apoptosis detection by enzyme linked immunosorbent
assay (ELISA)
Drug induced apoptotic cell death was assessed using the Cell
Death Detection ELISA kit (Roche Diagnostics), which quantitates
cytoplasmic histone associated DNA fragments in the form of
mononucleosomes or oligonucleosomes. Cells were seeded and
incubated at 10,000 cells per well in 12 well flat bottomed plates
in 10% FBS supplemented MEM medium. After 24 h, cells were
treatedwith compound 76 for 48 h at the indicated concentrations.
Both floating and adherent cells were collected and the assay was
done according to the manufacturer’s instructions.
Flow cytometry analysis
For all the assays, cells were treated for 48 h. To analyze the cell
cycle profile, treated cells were fixed overnight with 70% EtOH at
20 8C and stained with propidium iodide buffer [38 mM sodium
citrate (pH 7.5), 69mMpropidium iodide, and 120mg/mL RNase A].
For assessment of apoptosis, treated cells were labeled with 5mL
Annexin V FITC (Invitrogen) and 0.1mg propidium iodide (Sigma
Aldrich) in 100mL binding buffer [10mmol/L HEPES, 140 mmol/L
NaCl, and 2.5 mmol/L CaCl2 (pH 7.4)] containing 5 105 cells.
Samples were mixed gently and incubated at room temperature in
the dark for 15 min. Immediately before analysis by flow cytometry,
400mL bindingbufferwas added toeachsample. Two color analysis
of apoptosis was done using a BD FACSCalibur System (BD
Biosciences). Fluorescence compensation on the flow cytometer
was adjusted tominimize overlap of the FITC and propidium iodide
signals. A total of 1.2  104 cellswere acquired for each sample anda
maximum of 1  104 cells within the gated region were analyzed.
Western blot
Cells were cultured in 60 mm culture dishes and incubated
with DMSO or drugs for 48 h and then lysed with CelLytic M
(Sigma Aldrich) supplemented with protease inhibitor tablets
(Roche, Indianapolis, IN). Cell lysates were sonicated briefly to
reduce viscosity. Protein concentration was determined and
samples were stored at 70 8C until use. Sixty micrograms of
proteins for each sample were boiled with 1 loading buffer
(100 mmol/L DTT plus bromophenol blue) for 5 min. Samples were
then electrophoresed in 10% SDS polyacrylamide gel and trans
ferred to a Trans Blot nitrocellulose membrane (Bio Rad) using a
Trans Blot SD semidry transfer cell (Bio Rad) at 100 mA for 90 min.
The membrane was blocked for 2 h with 5% nonfat milk in 1 TBS
T at room temperature to reduce background and then incubated
with primary antibody, in 1% bovine serum albumin at 4 8C
overnight. After the membrane was incubated with the primary
antibody and washed four times with 1 TBS T for 5 min each
wash, it was incubated with the secondary antibody in 5% nonfat
milk for 60 min at room temperature. The membrane was washed
four times again for 5 min each time with 1 TBS T and incubated
with SuperSignal West Pico Chemiluminescent Substrate (Pierce)
according to the protocol of the manufacturer. The membrane blot
was exposed to Basic Autorad Film (ISC Bioexpress, Kaysville, UT)
and developed using a Konica SRX 101A (Konica, Tokyo, Japan).
The blot was reprobed with anti actin (Santa Cruz Biotechnology)
at 1:2000 dilution as a loading control. Anti pAKt, AKt, p ERK, ERK,
pBAD112, pBAD136, BAD, BAX, BCL 2, BCL XL were diluted
(1:1000).
Cytochrome c release
Drug treated cells were collected and lysed with 100 mL of
chilled hypotonic lysis solution [220 mmol/L mannitol, 68 mmol/L
sucrose, 50 mmol/L KCl, 5 mmol/L EDTA, 2 mmol/L MgCl2, and
1 mmol/L DTT in 50 mmol/L PIPES KOH (pH 7.4)] for 45 min. The
solution was centrifuged at 600  g for 10 min to collect the
supernatant. The supernatant was further centrifuged at
14,000 rpm for 30 min, and equal amounts of proteins (50 mg)
from the supernatant were resolved in 15% SDS polyacrylamide
gel. Proteins were transferred to nitrocellulose membranes and
analyzed by immunoblotting with anti cytochrome c antibodies
[25].
Statistical analysis
Statistical and graphical information was determined using
GraphPad Prism software (GraphPad Software Incorporated) and
Microsoft Excel (Microsoft Corporation). Determination of IC50
values were performed using nonlinear regression analysis.
Statistically significant differences were calculated with the
two tailed unpaired Student’s t test and P values reported at
95% confidence intervals.
Results
Characterization of five breast cancer cell lines
Five breast cancer cell lines from ATCC were determined for
their Her2 and estrogen receptor (ER) status by Western blot. The
results indicate that SKBR 3 and BT474 have the highest Her2
expression. MDA MB 453 has relatively lower Her2 expression,
and MCF 7 and MDA MB 231 do not have any detectable Her2
protein (Fig. 1 and Table 1). BT474 and MCF 7 cells have similar
level of ER expression, and the rest of them do not show any ER
band.
Anti proliferation activity of compound 76 on five
breast cancer cell lines
Compound 76 has been found to be effective in suppressing
SKBR 3 breast cancer cells proliferationwith an IC50 about 1.0 mM
[24]. However, it is unclear whether this compound is generally
cytotoxic to other breast cancer cells as well. To investigate the
selectivity of compound 76 on inhibiting breast cancer cell
growth, five breast cancer cell lines which include both Her2
positive and negative cells were used to explore the anti cancer
mechanisms of compound 76. The compound dose dependently
suppressed SKBR 3, BT474 and MDA MB 453 breast cancer cell
proliferation with IC50 at 0.9 mM, 2.2 mM and 4.0 mM, respec
tively. However, theywere not effective in suppressingMCF 7 and
MDA MB 231 breast cancer cell growth, with IC50 at 22.1 mMand
19.6 mM, respectively (Fig. 2A and Table 2). To further measure
the biological activity of the compound, itwas also tested in a time
course study with SKBR 3 and BT474 cells. The results revealed
that the compound did not cause acute cytotoxicity effect to the
cells. The cell viability dropped after 48 h of the compound
treatment (Fig. 2B and C). Within the five breast cancer cell lines,
compound 76 was more active in SKBR 3, BT474 and MDA MB
453 which are all Her2 overexpressing cells. It appears that
compound 76 was able to selectively inhibit Her2 overexpressing
breast cancer cell growth.
Table 1
Her2 and ER expression levels in five breast cancer cell lines.
BT474 SKBR-3 MDA-453 MCF-7 MDA-231
HER2 +++ +++ +  
ER +   + 
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Compound 76 induced cellular and nuclear morphology changes
Based on the cell proliferation studies, continuous exposure to
2.5 mM compound 76 for 48 h significantly reduced cell survival.
Cells undergoing apoptosis show typical morphological character
istics, including cell shrinkage, condensation of the nucleus, and
formation of apoptotic bodies. The effects of compound 76 on cell
morphology were examined with the fluorescent chromatin dye
Hoechst 33342 (Fig. 2D). A large portion of the SKBR 3 cells treated
with compound 76 at 2.5 mM and 5mM for 48 h stained with
Fig. 2. Compound 76 dose and time dependently inhibited breast cancer cell growth. Cells were exposed to compound 76 with various concentration and time intervals. Cell
viability was then measured by MTT assay as described in Section 2. The results were normalized against a control treatment with vehicle. Each data point represents the
mean results of six independent determinations  SD. (A) Compound 76 dose-dependently inhibited breast cancer cell growth. (B) Compound 76 time-dependently inhibited
SKBR-3 cell growth. (C) Compound 76 time-dependently inhibited BT474 cell growth. (D) Compound 76 induced cellular and nuclear morphology changes. The effects of compound
76 on cell morphologywere examinedwith the fluorescent chromatin dye Hoechst 33342 in SKBR-3 and BT474 cells. Cells were treatedwith compound 76 for 48 h and then stained
with the fluorescent chromatin dye for 30 min. Up two panels, SKBR-3 cell; lower two panels, BT474 cells.
Table 2
IC50 of compound 76 on inhibition of breast cancer cell growth. Cells exposed to
compound 76 with various concentrations for 72 h. Cell viability was then
measured by MTT assay as described in Section 2. The results were normalized
against a control treatment with vehicle. Each data points represent the mean
results of six independent determinations  SD. IC50 values were calculated by a
nonlinear regression analysis (GraphPad Prism).
SKBR-3 BT474 MCF-7 MD453 MD231
IC50 (mM) 0.89  0.14 2.17  0.24 22.10  3.76 3.93  0.53 19.58  2.16
1790
Hoechst 33342 had apoptotic bodies and/or irregularly punctate
nuclei, characteristic of cells undergoing programmed cell death
(Fig. 2D top panel). For BT474 cells (Fig. 2D bottom panel), this
effect was not very clear. The apoptosis bodies were clearly
observed only at 5mM treatment.
Compound 76 caused cell population concentrated
at sub G1 phase
Since compound 76 dramatically inhibited SKBR 3 and BT474
breast cancer cell growth, we hypothesized that it might cause cell
cycle arrest. However, in the SKBR 3 cell cycle study, a significant
amount of cells concentrated at the sub G1phase (Fig. 3 andTable 3)
after compound 76 treatment even at 1mM, which indicated cell
apoptosis. The G1/S ratio did not change significantly. Only after
5mM treatment, G1/Swas dramatically changed, mainly due to cell
death. This suggests that the compound did not cause cell cycle
arrest. It mainly induced apoptosis in SKBR 3 cells. However, this
effectwasnot significant inBT474cells. It is possible thatBT474cells
have bothHer2 andER expression and dependonboth pathways for
proliferation. These multiple growth pathways make cells easy to
survive under single treatment targeting only one pathway.
Measure apoptosis by using cell death detection ELISA
Induction of apoptosis was also assessed by using a Cell Death
Detection ELISA (Roche Diagnostics, Mannheim, Germany) after
compound 76 treatments in SKBR 3 and BT474 cells. This test is
based on the quantitative determination of cytoplasmic histone
associated DNA fragments in the form of mononucleosomes and
oligonucleosomes after induced apoptotic death (Fig. 4A and B).
Significant DNA fragments were shown in SKBR 3 cells after
compound 76 treatments at 2.5mM and 5mM for 48 h. In BT474
cells, only at 5mM was this effect observed.
Analysis apoptosis by cell flow cytometry and Western blot
Apoptosis was also detected by Annexin V analysis of
phosphatidylserine externalization as shown in Fig. 5. Normal
ization to the DMSO treated controls revealed that compound 76
at 2.5 mM and 5mM induced 18% and 66% apoptotic death
compared with 8% by DMSO in SKBR 3 cells after 48 h treatment,
respectively (Fig. 5A top panel). In BT474 cells, apoptotic cells were
not clearly shown in the panel at 5 mM treatment of compound 76
(Fig. 5A bottom panel). Furthermore, apoptosis was also char
acterized by Western blot analysis of PARP cleavage to the
apoptosis specific 85 kDa fragment and cytochrome c release
(Fig. 5B). After 48 h treatment of compound 76 at 5 mM or even
lower concentration, SKBR 3 cells showed clear 85 kDa fragment
and released cytochrome c band; for BT474 cells, both marks were
not very clear. All the results suggest that compound 76
dramatically induced apoptosis in SKBR 3 cells, but was not very
effective in BT474 cells compared with SKBR 3 cells.
Compound 76 did not affect Her2 downstream kinase activity,
nor the BCL family and BAD protein levels
To further explore the mechanisms of compound 76 inducing
apoptosis in Her2 over expressing breast cancer cells, PI3K/Akt and
MAPK kinases which are downstream of Her2 pathway were
determined after compound 76 treatments. The results exhibit that
pAkt, total Akt, pERK and total ERK remained the same in both cell
lines (Fig. 6). This suggests that the compound did not affect the
Her2 signal transduction. Previous cytochrome c release assay
results suggest that the apoptosis induced by compound 76 was
mediated from the mitochondria. Therefore, BCL 2, BCL XL, BAX,
BAD, and pBAD were also checked after compound 76 treatment.
The results reveal that compound 76 did not alter the concentra
tion of any of those apoptosis controlling proteins. It has been well
documented that the dimerization of those proteins is also the key
Fig. 3. Apoptosis induced by compound 76 confirmed in cell cycle study. SKRB-3 and BT474 cells were treated for 48 h in the presence of the indicated concentrations of
compound 76. Cells were processed for FACS using propidium iodide as described in Section 2.
Table 3
Summary of altered cell cycle distribution in response to treatment with compound
76. SKBR-3 and BT474 cells were treated for 48 h with the indicated concentrations
of compound. Cells were processed for FACS using propidium iodide and AnnexinV/
7-AAD staining as described. Percent distribution of cells in each cell cycle phase
was displayed.
Cell lines Compound 76 Sub-G1% G1% S % G2/M % Dead cells
SKBR-3 DMSO 3.04 65.79 20.19 9.01 1.97
1 (mM) 19.69 42.65 19.83 7.22 10.61
2.5 (mM) 18.77 44.15 20.8 8.17 8.11
5 (mM) 42.35 12.12 13.39 6.9 25.24
BT474 DMSO 9.13 58.12 21.96 7.63 3.16
1 (mM) 2.48 68.17 19.39 8.53 1.43
2.5 (mM) 2.31 69.1 18.99 8.04 1.56
5 (mM) 9.56 61.33 16.24 8.66 4.21
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reason of pro or anti apoptosis [26,27]. The compound might
interfere with the dimerization process to induce apoptosis.
However, the complexity of the dimerization makes it difficult to
focus on.
Discussion
Her2 gene amplification and resultant protein overexpression in
breast cancer are associated with a more aggressive clinical course
[2,9]. The Her2 receptor controls multiple pathways associated
with epidermal growth factor (EGFR) and Her receptor activation.
Furthermore, these pathways regulate proliferation, cell death,
angiogenesis and migration [3 8]. Therefore, aberrant expression
of Her2 receptors contributes significantly to the progression of
cancer. The overexpressed biological marker makes targeted
therapy possible in the cancer treatment. Several studies demon
strated that the inhibition of this receptor reduced the proliferative
capacity and increased apoptosis of Her2 overexpressing malig
Fig. 4. Cell death ELISA analysis of apoptosis in SKBR-3 and BT474 cells receiving compound 76 treatments. Effect of compound 76 treatment on cell nucleosomal
fragmentationwas evaluated. Cells were treated for 48 h in the presence of the indicated concentrations of compound 76. DNA fragmentationwas quantitativelymeasured by
a cell death detection ELISA kit. Columns, mean; bars, SD (n = 3). (A) SKBR-3 cells, (B) BT474 cells. *P < 0.05 vs. DMSO by unpaired t-test.
Fig. 5. Annexin V flow cytometric andWestern blot analysis of apoptosis in SKBR-3 and BT474 cells receiving compound 76 treatments. (A) Cells were treated for 48 h in the
presence of the indicated concentrations of compound 76 and thenwere processed for FACS by using Annexin V/propidium iodide staining as described in Section 2. Note that
the apoptotic population resides in the upper and lower right (UR + LR) panels of the Annexin V stained cells. (B) Compound 76 induce cytochrome c release and PARP cleavage
in both cell lines. Mitochondria-free lysates and total lysates were prepared as described in Section 2 for theWestern blot analysis of cytochrome c release and PARP cleavage,
respectively.
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nant cells [10]. In contrast to conventional anti cancer treatment
which target cellular machinery common to both malignant as
well as normal dividing cells, targeted therapy drugs are directed at
a more specific target resulting in lower toxicity.
Our goal is to identify newagents thatwould selectively inhibit
the growth of Her2 overexpressing breast cancer cells. Previous
studies reveal that nimesulide and its analogs could inhibit breast
cancer cell growth [24]. However, the inhibitory mechanism of
these agents is not defined. Nimesulide was found to inhibit the
proliferation of several breast cancer cell lines (SKBR 3, BT474,
MCF 7, MDA MB 231 cell lines) without any selectivity. The IC50
value for nimesulide to achieve this biological activity is around
100 150 mM [24]. It was felt that cell death resulted from general
cell toxicity was not worth further investigation. Compound 76,
which shares some structure similaritywith nimesulide and is the
most active one of the compound library, was systematically
investigated with several breast cancer cell lines. Although
compound 76 is an analog of COX 2 inhibitor nimesulide, it is
not a COX 2 inhibitor. For COX 2 inhibition, the sulfonamide
group is very critical in nimesulide and its derivatives (Fig. 1). Only
when the N H is available as the ionized form, the compounds
inhibit COX 2. Introduction of any group to the sulfonamide, such
as a methyl group to eliminate this ionization process, will
produce compounds without COX 2 inhibitory activity. Results
from previous PGE2 production experiments demonstrate that
the N methyl substituted nimesulide analogs do not exhibit COX
2 inhibitory activity [28]. Compound 76 has an N methyl
substituted sulfonamide group which eliminates it as a COX 2
inhibitor, which also suggests that the anti breast cancer activity
of compound 76 is COX 2 independent. The results presented here
show that compound 76 could dramatically inhibited Her2
overexpressing breast cancer cell proliferation at low micromole
concentrations. However, it was not very effective in Her2
negative breast cancer cells, and needed much higher concentra
tion to achieve similar biological activity. This indicates that
compound 76 might target Her2 related cellular machinery to
inhibit cell proliferation. Breast cancer cells that do not depend on
Her2 to grow were not sensitive to the compound. Because of the
typical apoptotic morphological changes including cell shrinkage
and condensation of the nucleus after compound 76 treatment,
several assays were performed to determine the possibility of
potential apoptosis inducing effects of compound 76 in Her2
overexpressing breast cancer cells. These assays included cell
cycle study, DNA staining, cell death detection ELISA, Annexin V
analysis of phosphatidylserine externalization, Western blot
analysis of PARP cleavage and cytochrome c release. With
SKBR 3 cells, compound 76 at 2.5 mM and 5 mM 48 h treatments
gave clearly positive results indicating apoptosis. However, for
BT474 cells, this effect was not very significant. In the DNA
staining, cell death detection ELISA and Annexin V analysis of
phosphatidylserine externalization studies, apoptosis was sig
nificant after the treatment. The rest of the experiments did not
show that compound 76 induced apoptosis in BT474 cells. It is
possibly due to themultiple pathwayswhich include Her2 and ER
in BT474 cells. Cells could use alternative pathways as compensa
tion after one was blocked by exogenous agents, which has been
reported in other studies [29]. SKBR 3 cells mainly depend on
Her2 to proliferate and were more sensitive to the treatment.
To further explore why compound 76 selectively induced
apoptosis in Her2 overexpressing breast cancer cells, Her2
downstream signals were determined after the treatment. The
results exhibited that compound 76 did not affect Akt and MAPK
pathways. Cytochrome c release assay results suggest that the
apoptosis was mediated through the mitochondria. However,
compound 76 did not change BCL 2, BCL XL, BAX, BAD and pBAD
protein levels. It is also possible that the compound could interfere
with the BAD and BCL 2 family protein dimerization to promote
cell apoptosis. However, the dimerization of these proteinswas not
clearly understood yet, which makes it difficult to further explore
the possible molecular target of the compound.
Fig. 6. Effects of compound 76 on theHer2 downstreampAKt, AKT, pERK, ERK expression and also the protein levels of Bad, Bax, BCL-2, BCL-XL in SKBR-3 and BT474 cells. Cells
were treated with the indicated concentrations of compound 76 for 48 h, and cell lysates were immunoblotted as described in Section 2.
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In conclusion,we investigated themechanismofcompound76 in
several breast cancer cell lines. The results demonstrated that the
compound could selectively induce apoptosis in Her2 overexpres
sing cells butwas lessactive inHer2negative cells.However, it is still
not clear the molecular target that the compound was aiming to
achieve this biological activity. Her2 overexpression could protect
the cells from apoptosis, and multiple downstream cell machinery
was involved in this process. Our results indicate that compound 76
promoted cell apoptosis through mitochondria. Although the
specific molecular target of the compound is still unclear, more
active analogs could be developed from compound 76. Lead
optimization of this compound to generate more potent derivatives
is undergoing in our laboratory.
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